Will Latest Dabigatran Data Finally Topple Warfarin?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
NEW ORLEANS - Boehringer Ingelheim's dabigatran etexilate had comparable efficacy and significantly lower or comparable bleeding rates to warfarin in patients with acute venous thromboembolism, according to data from the RE-COVER trial reported Dec. 6 at the American Society of Hematology meeting in New Orleans
You may also be interested in...
Bayer/J&J Will Resubmit Xarelto For Acute Indication In Second Half, Along With New Application For Chronic Use
Bayer/J&J plan to file the first chronic indication for their anticoagulant Xarelto, as well as respond to FDA on the "complete response" letter for their application for acute use in hip and knee replacement surgery, in the second half of 2010, Bayer CEO Werner Wenning announced Feb. 26 during the firm's 2009 year-end report
Bayer/J&J Will Resubmit Xarelto For Acute Indication In Second Half, Along With New Application For Chronic Use
Bayer/J&J plan to file the first chronic indication for their anticoagulant Xarelto, as well as respond to FDA on the "complete response" letter for their application for acute use in hip and knee replacement surgery, in the second half of 2010, Bayer CEO Werner Wenning announced Feb. 26 during the firm's 2009 year-end report
Specialty Pharma Canyon Takes Leech-Inspired Anticoagulant Approved In 2003 To Market
Iprivask, "the first direct thrombin inhibitor approved in the U.S.," was found superior to both heparin and Lovenox but fell through the cracks during pharma M&A activity, Canyon exec says.